COMP <GO>
XRAY vs LLY // FREE CASH FLOW YIELD
DENTSPLY SIRONA Inc. (NASDAQ) VS. Eli Lilly and Company (NYSE) • 15-METRIC TALLY: XRAY 2
— LLY 9
▲ FREE CASH FLOW YIELD LEADER: XRAY
LAST: $9.61 (+1.80%) • MKT CAP: $1.92B
fcf-yield
12.27%
LAST: $1,373.70 (+6.63%) • MKT CAP: $1.29T
fcf-yield
2.30%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (XRAY VS. LLY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | XRAY | LLY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 50.00% | 83.64% | -33.64 | LLY | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -11.00% | 32.36% | -43.36 | LLY | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 36.4x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield ACTIVE | 12.27% | 2.30% | +9.97 | XRAY | /fcf-yield <GO> |
| Operating Margin | -11.50% | 40.21% | -51.71 | LLY | /operating-margins <GO> |
| Net Profit Margin | -16.20% | 31.90% | -48.10 | LLY | /net-margins <GO> |
| Revenue Growth (YoY) | -3.00% | 45.51% | -48.51 | LLY | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 6.68% | 0.49% | +6.19 | XRAY | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.45 | 9.29 | -8.84 | LLY | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 9/9 | -3.00 | LLY | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | 6.77% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 55.1 | 66.6 | -11.53 | LLY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.51 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 26.3x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.92B | $1.29T | -$1.29T | LLY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | XRAY REV | LLY REV | XRAY GROSS % | LLY GROSS % | XRAY FCF | LLY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $3.68B | $65.18B | 50.0% | 83.0% | $235.0M | $16.81B |
| FY 2024 | $3.79B | $45.04B | 51.6% | 81.3% | $461.0M | $8.82B |
| FY 2023 | $3.96B | $34.12B | — | 79.3% | $377.0M | $4.24B |
| FY 2022 | — | $28.54B | — | 76.8% | — | $7.59B |
| FY 2021 | — | $28.32B | — | 74.2% | — | $7.37B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
XRAY // BETA —
LLY // BETA 0.51